News sentiment analysis powered by sentiment-insight.com
Gilead quarterly results beat Street estimates as...
Gilead quarterly results beat Street estimates as profit up on lower taxes. Sales of HIV drug Biktarvy rose 12% to $3.1 billion, which was in line with analysts' estimates.
Gilead quarterly results beat Street estimates as lower... Sales of HIV drug Biktarvy rose 12% to $3.1 billion, which was in line with analysts' estimates. Sales of COVID drug Veklury fell 31% but still came in well above Wall Street expectations of $363 million. Gilead raised its full-year forecast for adjusted earnings.
Class-Action Lawsuit Filed Against Remdesivir Manufacturer Over Alleged Deceptive Practices Two California residents, one of whom is a relative of a person who died after receiving remdesivir, lodged the suit against Gilead Sciences in Shasta County. The suit says the company downplayed or omitting altogether the clinical dangers experienced by patients.
Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today Gilead Sciences has grown its earnings per share (EPS) by 46% per year, over the last three years. The company's EBIT margins are down, but it's not all bad news as revenues are at least stable. With a whopping US$66m worth of shares as a group, insiders have plenty riding on the company's success. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics.
Morgan Stanley updated its portfolio of top stock picks which trounced the market in the last year CNBC Pro Talks: Planning your financial future from the world's largest wealth festival. Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America.
US STOCKS-S&P 500 closes up slightly ahead of US inflation data The S&P 500 closed slightly higher on Friday but well below its session high. All three of Wall Street's major averages posted weekly declines. Gilead Sciences added 2.8% after BofA Securities upgraded the drugmaker to "buy"
Stocks making the biggest moves midday: Kroger, DocuSign, Planet Labs, First Solar and more Hudson Pacific Properties slid 4.2% after suspending its common stock dividend. First Solar gained 1.4% after Deutsche Bank upgraded First Solar to buy from hold. Gilead Sciences gained 3% Friday after Bank of America upgraded the stock to buy.
Here's Why We Think Gilead Sciences (NASDAQ:GILD) Is Well Worth Watching Gilead Sciences has achieved impressive annual EPS growth of 46%, compound, over the last three years. The large insider ownership only serves to further stoke our interest. At times fast EPS growth is a sign the business has reached an inflection point, so there's a potential opportunity to be had here.
Two Brands Suspend Twitter Advertising After Appearing on Pro-Nazi Account Social media platform X, previously known as Twitter, has been suspended after at least two brands cut their advertising for appearing on the profile. A report revealed how brands including Sports Illustrated, Gilead Sciences, USA Today, NCTA-The Internet and Television Association and more appeared on the verified profile.
X suspends pro-Hitler account after major brands including pharma giant Gilead pause ads Gilead Sciences, the California-based pharmaceutical giant, and NCTA — The Internet & Television Association, a trade association representing telecommunications companies, said they halted their ads on X. The move was made after the liberal watchdog group Media Matters for America reported that several companies’ ads had appeared on an X profile titled “New American Union.” A source familiar with the situation told The Post that the two brands lifted their pause and resumed advertising on the platform.
Gilead ties up with Tentarix for cancer, inflammatory... Gilead Sciences said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases. Gilead earlier this month flagged a more than 25% jump in research and development costs.
Gilead quarterly profit falls on COVID sales drop,... Gilead quarterly profit falls on COVID sales drop, legal settlement charge. Sales of Gilead's HIV portfolio rose 9% to $4.63 billion, with Biktarvy bringing in $2.98 billion.
Gilead quarterly profit falls on COVID sales drop, legal settlement charge Gilead Sciences reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment. Drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations.
How a drugmaker profited by slow-walking a promising HIV therapy Gilead, one of the world's largest drugmakers, faces state and federal lawsuits from some 26,000 patients. In 2004, Gilead Sciences decided to stop pursuing a new HIV drug.
Pay for Delay: Big Pharma’s Most Maddening Business Tactic The original federal antitrust law, the Sherman Act of 1890, outlaws “every contract, combination, or conspiracy’ Gilead allegedly paid Teva not to compete against it for several years. Under traditional antitrust principles, this should be unlawful.
Cramer's Lightning Round: Stay away from Gilead Sciences Gilead Sciences: "No. This stock has got epoxy on its feet! We want stocks to go higher" Bank of Hawaii: "Right now I'm only recommending two bank stocks, I'm recommending Wells Fargo and Morgan Stanley"
Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today Gilead Sciences (NASDAQ:GILD) has been growing its earnings per share by 4.5% per year. The company is a growing business, which is encouraging. There is also notable levels of insider ownership. It's still necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Gilead sciences, and understanding these should be part of your investment process.
Jury rules for drugmaker, dealing blow to U.S. over HIV patent lawsuit Jurors in the U.S. district court in Delaware found in favor of Gilead on all counts. The Justice Department declined to comment. The dispute goes back to the mid-2000s, when CDC scientists discovered that combining two drugs could effectively prevent the spread of HIV.
Gilead Sciences didn't violate government patents on HIV prevention treatment, jury finds The U.S. government had sued Gilead in 2019 arguing that the company was profiting off CDC patents. The jury found that the government's patent claims on an HIV prevention regimen were not valid after a multiday trial.
Trial set for drugmaker accused of profiting from government patents Gilead Sciences is accused of infringing on patents obtained by the U.S. Centers for Disease Control and Prevention. Gilead, with a stock market value of roughly $100 billion, has fought back aggressively, arguing the CDC’s patents are invalid.
Sign Up
